References
van Seijen M, Lips EH, Thompson AM, et al. Ductal carcinoma in situ: to treat or not to treat, that is the question. Br J Cancer. 2019;121(4):285–92.
Narod SA, Iqbal J, Giannakeas V, Sopik V, Sun P. Breast cancer mortality after a diagnosis of ductal carcinoma in situ. JAMA Oncol. 2015;1(7):888–96.
Weinmann S, Leo MC, Francisco M, et al. Validation of a ductal carcinoma in situ biomarker profile for risk of recurrence after breast-conserving surgery with and without radiotherapy. Clin Cancer Res. 2020;26(15):4054–63.
Hwang ES, Hyslop T, Lynch T, et al. The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). BMJ Open. 2019;9(3):e026797.
Komm BS, Mirkin S, Jenkins SN. Development of conjugated estrogens/bazedoxifene, the first tissue selective estrogen complex (TSEC) for management of menopausal hot flashes and postmenopausal bone loss. Steroids. 2014;90:71–81.
Ethun KF, Wood CE, Register TC, Cline JM, Appt SE, Clarkson TB. Effects of bazedoxifene acetate with and without conjugated equine estrogens on the breast of postmenopausal monkeys. Menopause. 2012;19(11):1242–52.
Funding
This research is funded by National Cancer Institute, Grant No. RO1CA218436, California Breast Cancer Research Program and Dancing with the Chicago Celebrities.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Disclosure
The authors declare they have no conflicts of interest and nothing to disclose.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Verbus, E.A., Khan, T.M., Hernandez, J.M. et al. Evaluating the Effects of a Tissue Selective Estrogen Complex (TSEC) in Women with Newly Diagnosed Ductal Carcinoma In Situ. Ann Surg Oncol 29, 2769–2770 (2022). https://doi.org/10.1245/s10434-021-11169-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-021-11169-6